Biosenic · EURONEXT:BIOS
Biosenic — Investor Presentation (January 2024)
24 slides from Biosenic's investor presentation, January 2024
Slide 1: Company Presentation: Autoimmunity and Cell Repair
Company Presentation Autoimmunity and Cell Repair “It is estimated that today 5 to 8% of the world's population is affected by an autoimmune disease (INSERM France).” January 2024
Slide 2: Disclaimer
Disclaimer This Presentation ("the Memorandum") is intended solely for informational use by prospective corporate partners of BioSenic SA and and its subsidiary, Medsenic SAS. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Transa
Slide 3: Profile
PROFILE Dual listing on Euronext Brussels and Paris, Compartment C Creation of BioSenic on October 2022: Reverse merger of Medsenic and Bone Late-stage biotech Therapeutics Mature organisation: 17 years in Belgium: Liège and Brussels Universities, Belgium & 13 years in France France: University René
Slide 4: Experienced Top Management Team
Experienced Top Management Team President Deputy CEO CSO-COO CMO CIRO François Rieger, PhD Véronique Pomi Carole Nicco, PhD Lieven Huysse, MD Alexia Rieger • Neurobiologist, • Founder and manager of • Doctor of Science, PhD • Medical degree, University • Bachelor from the • Former CNRS Research ARC
Slide 5: Experienced Board Team
Experienced Board Team François Jean Stephenne Jean-Luc Jean-François Véronique Pomi1 Yves Sagot, PhD Revital Rieger1, PhD Vandebroek Rax Rattenbach, PhD 5
Slide 6: Our Mission
OUR MISSION Bringing patients innovative treatments in severe and persistent autoimmune/inflammatory diseases and cell repair ARSENIC TRIOXIDE PLATFORM ALLOB®* PLATFORM ➔ Successful phase II completed for ATO* ➔ Phase III in preparation ➔ Ongoing discussions for licensing ➔ Estimated go to market in
Slide 7: Significant milestones expected in 2024 from our late stage clinical pipeline
Significant milestones expected in 2024 from our late stage clinical pipeline Preclinical Phase I Phase IIa Phase IIb Phase III Next steps OATO Ph III to start Chronic Graft vs 2024 after In preparation* Host Disease IND (cGVHD) submission Conclusive JTA-004 post hoc analysis Licencing in Osteoarthr
Slide 8: Significant milestones expected in 2024 from our late stage clinical pipeline
Significant milestones expected in 2024 from our late stage clinical pipeline Preclinical Phase I Phase IIa Phase IIb Phase III Next steps OATO Ph III to start ARSCICOR Chronic Graft vs In 2024 after IND (Oral) Host Disease preparation* (cGVHD) submission ALLOB® Positive PhIIa ALLOB Licencing in Tib
Slide 9: Arsenic Trioxide platform
Arsenic Trioxide platform Intravenous / oral formulation
Slide 10: Our Technology IP - ATO: Arsenic Trioxide platform
OUR TECHNOLOGY IP - ATO : Arsenic Trioxide platform Intravenous / oral formulation The immunomodulatory properties of ATO have demonstrated multiple effects targeting overactivated cells: immunomodulation or cell-death ● Exclusive early WW license from CNRS to use Arsenic in autoimmune diseases & in
Slide 11: Our lead arsenic products target severe & persistent inflammation
Our lead arsenic products target severe & persistent inflammation cGvHD (rare disease): Lupus : Systemic Sclerosis (rare disease): Multisystem disorder triggered by active Chronic auto-immune disease Autoimmune disorder that affects the skin immune of donor T cells that attack characterized by chron
Slide 12: Preclinic - Clinic: ATO in cGvHD
Preclinic - Clinic ATO in cGvHD
Slide 13: Chronic GVHD
Chronic GVHD Severe skin and lung cGVHD are challenging manifestations leading to death Preclinical Clinical N Engl J Med 377;26 nejm.org December 28, 2017 13
Slide 14: Market Analysis
tI BioSenic Market Analysis 14
Slide 15: Competitiveness: no effective treatment on the market
Competitiveness: no effective treatment on the market BioSenic’s lead candidate, ATO, is one of the most clinically advanced, in addition of being the only one considered, as first line treatment. However, other drugs are currently under study as second or third line treatment (often repositioning).
Slide 16: cGvHD clinical trial
cGvHD clinical trial Conducted by BioSenic 16
Slide 17: Arsenic for autoimmune diseases in phase 2 clinical trials
Arsenic for autoimmune diseases in phase 2 clinical trials (Results published in Q2 2022 in the Journal of Transplantation and Cellular Therapy) Restricted Population Full Analysis Set (Perfect Protocol Responses Population Followers) (N=20) (N=17) Complete and Partial 15pts /20 pts : 75.0% 14pts/17
Slide 18: 2024, a decisive year ahead
2024, a decisive year ahead 18
Slide 19: An out-licensing business model
An out-licensing business model Stable cash consuming within a highly valued market 1 2 3 4 Innovative approach Agile organization Out-licensing model Efficacy and safety based on Decentralized R&D Marketing model already deployment of new Outsourced including partners demonstrated on treatments usi
Slide 20: 2024, a decisive year with important milestones ahead
2024, a decisive year with important milestones ahead Stable cash consuming within a highly valued market Organization Clinical Business achievements Reinforce the Industrial partners search management team to Commercial partners Phase III initiation in execute the roadmap search cGVHD 2024 ● Appoin
Slide 21: An out-licensing business model
An out-licensing business model Stable cash consuming within a highly valued market 1 2 3 4 Innovative approach Agile organization Out-licensing model Efficacy and safety based on Decentralized R&D Marketing model already deployment of new Outsourced including partners demonstrated on treatments usi
Slide 22: Financial items
Financial items Financial calendar Shareholders’ structure as of 12/01/2023 ● April 25, 2024: Full Year Results & Annual Report ● May 27, 2024: Q1 Business and Financial Highlights ● June 12, 2024: General Meeting of Shareholders ● September 5, 2024: 2023 H1 results ● October 28, 2023: 2023 Q3 activ
Slide 23: Why invest in BioSenic?
Why invest in BioSenic? 2 main platform assets: one under clinical development, the other ready for licencing 2 platforms, and strong synergies for innovative inflammatory, autoimmune or repair treatments A Phase 3, first line oral treatment of cGvHD using proven benefits of Arsenic Orphan drug desi
Slide 24: Alexia Rieger, Investor Relations
Alexia Rieger Investor Relations alexia.rieger@biosenic.com +33617281245 24